Paratek Pharmaceuticals, Inc. (PRTK)

Market Cap	116.10M
Revenue (ttm)	116.51M
Net Income (ttm)	-88.66M
Shares Out	55.55M
EPS (ttm)	-1.72
PE Ratio	n/a
Forward PE	1.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	205,393
Open	2.10
Previous Close	2.11
Day's Range	2.07 - 2.14
52-Week Range	1.60 - 4.37
Beta	1.48
Analysts	Buy
Price Target	18.36 (+778.47%)
Earnings Date	Mar 13, 2023

About PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracy...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Evan Loh
• Employees: 207
• Stock Exchange: NASDAQ
• Ticker Symbol: PRTK

Financial Performance

In 2021, PRTK's revenue was $130.16 million, an increase of 177.39% compared to the previous year's $46.92 million. Losses were -$59.08 million, -38.80% less than in 2020.

Analyst Forecast

According to 9 analysts, the average rating for PRTK stock is "Buy." The 12-month stock price forecast is $18.36, which is an increase of 778.47% from the latest price.

Price Target

$18.36

(778.47% upside)

Analyst Consensus: Buy